vs
Side-by-side financial comparison of Arhaus, Inc. (ARHS) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $364.8M, roughly 1.9× Arhaus, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 4.1%, a 14.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 5.1%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-8.8M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 11.2%).
Arhaus, Inc.ARHSEarnings & Financial Report
Arhaus, Inc. is an upscale American home furnishings company headquartered in Boston Heights, Ohio. Founded in 1986 with a focus on sustainability and artisanship in product quality, Arhaus provides a diversified assortment of specialty goods and services addressing omnichannel direct-to-consumer and business-to-business residential and commercial operations.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ARHS vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $364.8M | $708.5M |
| Net Profit | $15.1M | $135.1M |
| Gross Margin | 38.1% | — |
| Operating Margin | 5.6% | 21.6% |
| Net Margin | 4.1% | 19.1% |
| Revenue YoY | 5.1% | 32.0% |
| Net Profit YoY | -29.1% | 15.5% |
| EPS (diluted) | $0.11 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $364.8M | $708.5M | ||
| Q3 25 | $344.6M | $659.9M | ||
| Q2 25 | $358.4M | $603.3M | ||
| Q1 25 | $311.4M | $558.6M | ||
| Q4 24 | $347.0M | $536.6M | ||
| Q3 24 | $319.1M | $533.3M | ||
| Q2 24 | $309.8M | $528.1M | ||
| Q1 24 | $295.2M | $511.0M |
| Q4 25 | $15.1M | $135.1M | ||
| Q3 25 | $12.2M | $111.1M | ||
| Q2 25 | $35.1M | $90.3M | ||
| Q1 25 | $4.9M | $114.6M | ||
| Q4 24 | $21.3M | $117.0M | ||
| Q3 24 | $9.9M | $96.4M | ||
| Q2 24 | $22.2M | $88.4M | ||
| Q1 24 | $15.1M | $102.6M |
| Q4 25 | 38.1% | — | ||
| Q3 25 | 38.7% | — | ||
| Q2 25 | 41.4% | — | ||
| Q1 25 | 37.1% | — | ||
| Q4 24 | 40.0% | — | ||
| Q3 24 | 38.6% | — | ||
| Q2 24 | 40.1% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 5.6% | 21.6% | ||
| Q3 25 | 4.8% | 21.5% | ||
| Q2 25 | 13.0% | 20.9% | ||
| Q1 25 | 1.7% | 20.3% | ||
| Q4 24 | 8.2% | 23.4% | ||
| Q3 24 | 3.3% | 21.1% | ||
| Q2 24 | 9.5% | 19.9% | ||
| Q1 24 | 6.2% | 20.4% |
| Q4 25 | 4.1% | 19.1% | ||
| Q3 25 | 3.5% | 16.8% | ||
| Q2 25 | 9.8% | 15.0% | ||
| Q1 25 | 1.6% | 20.5% | ||
| Q4 24 | 6.1% | 21.8% | ||
| Q3 24 | 3.1% | 18.1% | ||
| Q2 24 | 7.2% | 16.7% | ||
| Q1 24 | 5.1% | 20.1% |
| Q4 25 | $0.11 | $4.65 | ||
| Q3 25 | $0.09 | $3.86 | ||
| Q2 25 | $0.25 | $3.10 | ||
| Q1 25 | $0.03 | $3.67 | ||
| Q4 24 | $0.15 | $3.67 | ||
| Q3 24 | $0.07 | $3.01 | ||
| Q2 24 | $0.16 | $2.75 | ||
| Q1 24 | $0.11 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $253.4M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $418.2M | $459.1M |
| Total Assets | $1.4B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $253.4M | $497.0M | ||
| Q3 25 | $262.2M | $285.4M | ||
| Q2 25 | $234.8M | $46.3M | ||
| Q1 25 | $214.4M | $441.4M | ||
| Q4 24 | $197.5M | $669.4M | ||
| Q3 24 | $177.7M | $656.9M | ||
| Q2 24 | $174.2M | $510.9M | ||
| Q1 24 | $233.2M | $407.0M |
| Q4 25 | $418.2M | $459.1M | ||
| Q3 25 | $400.4M | $293.6M | ||
| Q2 25 | $385.6M | $172.4M | ||
| Q1 25 | $348.8M | $593.6M | ||
| Q4 24 | $343.7M | $825.5M | ||
| Q3 24 | $320.6M | $881.4M | ||
| Q2 24 | $309.3M | $763.6M | ||
| Q1 24 | $285.6M | $671.5M |
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.2B | $2.1B | ||
| Q3 24 | $1.2B | $2.1B | ||
| Q2 24 | $1.2B | $1.9B | ||
| Q1 24 | $1.2B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.3M | $192.7M |
| Free Cash FlowOCF − Capex | $-8.8M | $188.1M |
| FCF MarginFCF / Revenue | -2.4% | 26.6% |
| Capex IntensityCapex / Revenue | 5.0% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.62× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $59.0M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.3M | $192.7M | ||
| Q3 25 | $46.1M | $246.2M | ||
| Q2 25 | $34.9M | $148.5M | ||
| Q1 25 | $46.5M | $125.8M | ||
| Q4 24 | $31.7M | $190.7M | ||
| Q3 24 | $31.1M | $149.1M | ||
| Q2 24 | $47.5M | $116.4M | ||
| Q1 24 | $36.8M | $152.7M |
| Q4 25 | $-8.8M | $188.1M | ||
| Q3 25 | $28.0M | $235.5M | ||
| Q2 25 | $20.9M | $142.4M | ||
| Q1 25 | $18.9M | $115.8M | ||
| Q4 24 | $13.0M | $183.0M | ||
| Q3 24 | $4.6M | $138.5M | ||
| Q2 24 | $11.3M | $103.5M | ||
| Q1 24 | $10.9M | $147.2M |
| Q4 25 | -2.4% | 26.6% | ||
| Q3 25 | 8.1% | 35.7% | ||
| Q2 25 | 5.8% | 23.6% | ||
| Q1 25 | 6.1% | 20.7% | ||
| Q4 24 | 3.7% | 34.1% | ||
| Q3 24 | 1.4% | 26.0% | ||
| Q2 24 | 3.6% | 19.6% | ||
| Q1 24 | 3.7% | 28.8% |
| Q4 25 | 5.0% | 0.6% | ||
| Q3 25 | 5.3% | 1.6% | ||
| Q2 25 | 3.9% | 1.0% | ||
| Q1 25 | 8.9% | 1.8% | ||
| Q4 24 | 5.4% | 1.4% | ||
| Q3 24 | 8.3% | 2.0% | ||
| Q2 24 | 11.7% | 2.4% | ||
| Q1 24 | 8.8% | 1.1% |
| Q4 25 | 0.62× | 1.43× | ||
| Q3 25 | 3.77× | 2.22× | ||
| Q2 25 | 1.00× | 1.65× | ||
| Q1 25 | 9.53× | 1.10× | ||
| Q4 24 | 1.49× | 1.63× | ||
| Q3 24 | 3.14× | 1.55× | ||
| Q2 24 | 2.14× | 1.32× | ||
| Q1 24 | 2.44× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARHS
| Sales Channel Retail | $305.7M | 84% |
| Sales Channel E Commerce | $59.2M | 16% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
